Cat. No.: HY-N0107

Cyclovirobuxine D

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction.

For research use only. We do not sell to patients.

Purity: 99.70%
CAS No.: 860-79-7
Formula: C₂₆H₄₆N₂O
Molecular Weight:402.66

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Cyclovirobuxine D Chemical Structure

CAS No.: 860-79-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR^[1]. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis^[2]. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction^[3].

All mTOR Isoforms :

All Akt Isoforms :

In Vitro

Cyclovirobuxine D (0-240 μM ;24-72 hours) shows a concentration- and time-dependent reduced cell viability after CVB-D treatment, only 10% MGC-803 cells and 20% MKN28 cells are alive at 72 h after treatment with 240 μM^[2].
Cyclovirobuxine D (0-120 μM; 48 hours) arrests the cell cycle of gastric cancer cells at S phase in a concentration-dependent manner^[2].
Cyclovirobuxine D (0-120 μM; 48 hours) leads to apoptosis in gastric cancer cells in a concentration-dependent manner, especially early stage apoptosis. Cyclovirobuxine D (0-120 μM; 48 hours) causes apoptosis via up-regulation of the apoptosis- related proteins, cleaved Caspase-3 and ratio of Bax/Bcl-2, in gastric cancer cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

MGC-803 and MKN28 cells
Concentration:

0, 30, 60, 120 and 240 µM
Incubation Time:

24, 48, 72 hours
Result:

Reduced Cell Viability and Colony Formation Ability of Gastric Cancer Cells

Cell Cycle Analysis^[2]

Cell Line:

MGC-803 and MKN28 cells
Concentration:

0, 30, 60, and 120 µM
Incubation Time:

48 hours
Result:

Arrested cell cycle progressions of MGC-803 and MKN28 cells.

Apoptosis Analysis^[2]

Cell Line:

MGC-803 and MKN28 cells
Concentration:

0, 30, 60, and 120 µM
Incubation Time:

48 hours
Result:

Induced apoptosis of MGC-803 and MKN28 cells.

Western Blot Analysis^[2]

Cell Line:

MGC-803 and MKN28 cells
Concentration:

0, 30, 60, and 120 µM
Incubation Time:

48 hours
Result:

Up-regulated cleaved Caspase-3 and Bax and decreased the expression of Bcl-2 expression.

Chemical Information

CAS No. 860-79-7
Appearance Solid
Molecular Weight 402.66
Formula C₂₆H₄₆N₂O
Color White to off-white
SMILES

C[C@H](NC)[C@@]1([H])[C@H](O)C[C@@]2(C)[C@]3([H])CC[C@@]4([H])C(C)(C)[C@@H](NC)CC[C@]4(C5)[C@]35CC[C@@]21C
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Pathol Res Pract

Assessment of anti-cancer activity of cyclovirobuxine D in nasopharyngeal carcinoma cells: Involvement of KIF23-mediated Akt/mTOR pathway. [Abstract]

2025 Sep 1:275:156204. PMID: 40902449

Solvent & Solubility

In Vitro:

Ethanol : 13 mg/mL (32.29 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4835 mL

12.4174 mL

24.8348 mL

5 mM

0.4967 mL

2.4835 mL

4.9670 mL

10 mM

0.2483 mL

1.2417 mL

2.4835 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 1.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 1.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 1.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lu J, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. Epub 2014 Apr 24. [Content Brief]

[2]. Wu J, et al. Cyclovirobuxine D Inhibits Cell Proliferation and Induces Mitochondria-Mediated Apoptosis in Human Gastric Cancer Cells. Molecules. 2015 Nov 19;20(11):20659-68. [Content Brief]

[3]. Yu B, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol	1 mM	2.4835 mL	12.4174 mL	24.8348 mL	62.0871 mL
	5 mM	0.4967 mL	2.4835 mL	4.9670 mL	12.4174 mL
	10 mM	0.2483 mL	1.2417 mL	2.4835 mL	6.2087 mL
	15 mM	0.1656 mL	0.8278 mL	1.6557 mL	4.1391 mL
	20 mM	0.1242 mL	0.6209 mL	1.2417 mL	3.1044 mL
	25 mM	0.0993 mL	0.4967 mL	0.9934 mL	2.4835 mL
	30 mM	0.0828 mL	0.4139 mL	0.8278 mL	2.0696 mL

Keywords

Cyclovirobuxine D

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cyclovirobuxine D

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cyclovirobuxine D

All mTOR Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cyclovirobuxine D Related Classifications

Cat. No.: HY-N0107